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Abstract
Staphylococcus epidermidis is the most important pathogen in infections related to implanted foreign materials, especially prosthetic joint
infections (PJIs). The aim of this study was to investigate the antimicrobial activities of 16 antibiotics against S. epidermidis isolated from
PJIs, with special focus on rifampicin and rpoB variability. Ninety-one per cent of the isolates were multiresistant (i.e. resistant to
members of more than three classes of antibiotics). Thirty-nine per cent were resistant to rifampicin, associated with one or two
single-nucleotide polymorphisms (SNPs) in rpoB. Using IsoSensitest agar with supplements, 61% were resistant to oxacillin, and using
Mueller–Hinton II agar with supplement, 84% were resistant. Using the Etest, 58% were resistant to cefoxitin, and using the disk
diffusion test, 91% were resistant. The mecA gene was detected in 85% of the isolates. Regarding recently available antibiotics, all
isolates were susceptible to tigecycline and linezolid, and 97% were susceptible to daptomycin. In addition, two novel antibiotics,
dalbavancin and ceftobiprole, were tested, although not yet available for routine use. The MIC50 and MIC90 values of these novel anti-
biotics were 0.032 and 0.047 mg/L and 0.5 and 1.5 mg/L, respectively. Among the other antibiotics, the rates of resistance varied
between 0% (vancomycin) and 82% (trimethoprim–sulphamethoxazole). S. epidermidis strains causing PJIs often show multiresistance,
including resistance to rifampicin, which is mainly caused by one or two SNPs. Some of the newer antimicrobial agents may provide
alternatives for monotherapy or combination therapy with rifampicin. Detection of mecA is necessary before initiating treatment of
infections due to S. epidermidis when it displays intermediate susceptibility to cefoxitin.
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Introduction
Staphylococcus epidermidis is a commensal of the human skin
ﬂora. Although the pathogenic potential and virulence factors
of this bacterium are relatively unknown [1,2], it has
emerged as the most important pathogen in infections
related to implanted foreign materials, especially prosthetic
joint infections (PJIs) [3].
Joint replacement surgery is one of the major medical
advances during the 20th century and has improved the qual-
ity of life for hundreds of thousands of patients. In Sweden,
approximately 14 000 hip joint replacements and 10 500
knee arthroplasties are performed annually. The main rea-
sons for arthoplasty revisions in Sweden are aseptic loosen-
ing or infection, which may be of early, delayed or late onset
(Swedish National Hip Arthroplasty Register, Annual report
2006, http://www.jru.orthop.gu.se; Swedish National Knee
Arthroplasty Register, Annual report 2007, http://www.
knee.nko.se). Among the patients who have had primary hip
joint replacements, 1.5% will be re-operated on within
2 years, 0.6% because of infection (Swedish National Hip
Arthroplasty Register).
Overall, the prevalence of primary infections following
joint replacements in Sweden has been reported to be
approximately 0.5% for hip PJI and 1% for knee PJI [4].
Although rare, implant infections represent a diagnostic and
therapeutic challenge for the doctor and cause considerable
suffering for the patient, with pain and disability and even
increased mortality. In addition, the costs are signiﬁcantly
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increased due to prolonged hospitalization, revision surgery
and long-term antimicrobial treatment [5].
The antimicrobial treatment of PJIs has, during the last
decades, consisted primarily of cell wall synthesis-inhibiting
antibiotics such as isoxazolyl-penicillins or glycopeptides [6].
However, without prosthetic joint exchange surgery, the
long-term outcome has been disappointing with ﬁnite treat-
ment regimens [7,8]. The main reason for this is that S. epide-
rmidis, which is the most common cause of PJIs [3], when
accumulating on a surface such as an implant, produces
bioﬁlm and switches to a stationary growth phase that is
inﬂuenced by high cell population densities [9,10]. Slow-
growing bacteria in a stationary phase, as compared with
planktonic bacteria, show reduced metabolic activity and,
thereby, increased resistance to killing by growth-dependent
antibiotics, e.g. cell-wall-active antibiotics [11,12]. In addition,
the bioﬁlm reduces the accessibility of antibiotics and host
immune components such as complement and antibodies
[13].
Optimal antibiotics for the treatment of foreign-body
infections have been proposed [14]. Experimental studies
[15,16] and clinical trials [17,18] have demonstrated
impressive results with rifampicin. However, the risk of
rapid development of resistance is a major problem [6],
and rifampicin should not be used as monotherapy.
Accordingly, various antibiotics, e.g. ﬂuoroquinolones [8],
fusidic acid [17,19], clindamycin [18] and linezolid [20],
have been proposed to be combined with rifampicin in
order to reduce the risk of development of rifampicin
resistance. Furthermore, some recently available antibiotics,
e.g. daptomycin, tigecycline and dalbavancin, may be
suitable for treatment of foreign-body infections, including
PJIs, caused by sessile and bioﬁlm-producing bacteria such
as S. epidermidis [21,22].
The aim of the present study was to investigate the
antimicrobial activities of 16 antibiotics against S. epidermidis
isolated from PJIs, with special focus on rifampicin and on
rpoB variability.
Materials and methods
Bacterial isolates
Thirty-three S. epidermidis isolates obtained during revision
surgery for PJIs with extraction or exchange were analysed.
Multiple tissue biopsy samples, usually ﬁve or more, were
taken, most of which yielded growth of S. epidermidis. Eleven
isolates were collected from patients with infected hip pros-
theses treated at Linko¨ping University Hospital, Sweden
(centre A) from 1993 to 2003, and 22 isolates were obtained
from patients with infected hip (n = 13), knee (n = 8) and
elbow joint prostheses (n = 1) treated at O¨rebro University
Hospital, Sweden (centre B) from 2000 to 2005.
At centre A, the tissue samples were immediately placed
into thioglycollate medium broth (3.0% BBL Thioglycollate
Medium (BD Diagnostic Systems, Sparks, MD, USA)) and
cultured at 37C for 5 days under aerobic conditions and for
10 days under anaerobic conditions. At centre B, the sam-
ples were cultured on Difco GC Medium Base (BD Diagnos-
tic Systems) supplemented with 1% haemoglobin powder,
10% horse serum (SVA, Uppsala, Sweden) and 1% IsoVitalex
Enrichment (BD Diagnostic Systems) at 36C under 5% CO2
for 2 days and on anaerobe agar medium (Fastidious anaer-
obe agar (Acumedia; Neogen Corporation, Lansing, MI, USA)
supplemented with 5% horse blood (SVA)) at 36C anaerobi-
cally for up to 5 days, as well as in enrichment broth (29.7%
fastidious anaerobic broth (Lab M, Bury, UK) supplemented
with 10% D-glucose (J. T. Baker, Deventer, The Nether-
lands)) for 7 days.
The isolates were stored at )70C in glycerol storage
broth [23] or in preservation medium (Trypticase soy broth
(BD Diagnostic Systems) supplemented with 0.3% Yeast
extract (BD Diagnostic Systems) and 29% horse serum
(SVA)) until further analysis.
The S. epidermidis isolates were veriﬁed to species level
using the ID32Staph system (bioMe´rieux, Marcy l’Etoile,
France) and sequencing of rpoB, as previously described [24].
Antibiotic susceptibility testing
The MICs of antibiotics (n = 16) were determined using the
Etest (AB Biodisk, Solna, Sweden), (Table 1). The disk
diffusion test (DDT) was performed for cefoxitin (10 lg),
moxalactam (30 lg) and norﬂoxacin (10 lg). All tests, except
for oxacillin susceptibility, were performed on IsoSensitest
agar (Oxoid, Basingstoke, UK) (ISOAP) with incubation for
16–18 h at 36C. Oxacillin susceptibility was tested, ﬁrstly, on
IsoSensitest agar (Oxoid) supplemented with 5% deﬁbrinated
horse blood (SVA) and 2% NAD (Sigma-Aldrich Inc., St Louis,
MO, USA) (ISONP) that was incubated for 24 h at 30C, and
secondly, on Mueller–Hinton II agar (BD Diagnostic Systems),
supplemented with 2% sodium chloride (MUHSP), that was
incubated for 16–18 h at 36C. The susceptibility testing was
done and breakpoints were established according to the
recommendations of the Swedish Reference Group for
Antibiotics (SRGA; http://www.srga.org).
Isolation of genomic DNA from the S. epidermidis isolates
For DNA isolation, the MagNA pure compact system with
the MagNA pure compact nucleic acid isolation kit I was
used according to the instructions of the manufacturer
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(Roche Diagnostics GmbH, Mannheim, Germany). The DNA
preparations were stored at +4C prior to PCR.
Detection of mecA
The mecA gene was detected using a real-time PCR as
described previously [25].
Nucleotide sequence determination of rpoB and sequence
analysis
Real-time PCR ampliﬁcation and sequencing of rpoB, as well
as subsequent sequence analysis, were performed as previ-
ously described [24].
Results
The results of antibiotic susceptibility testing, using the Etest,
of 16 antibiotics are summarized in Table 1.
Thirty-nine per cent of the isolates were resistant to
rifampicin (MIC >32 mg/L, n = 12; MIC 6 mg/L, n = 1).
Rifampicin resistance was associated with one or two single-
nucleotide polymorphisms (SNPs) in rpoB (Fig. 1), whereas
the rpoB sequences were identical for all susceptible isolates
(n = 20), except one, which had a non-synonymous SNP
that resulted in the amino acid change A477V (Fig. 1).
Among the resistant isolates (n = 13), the amino acid
changes were as follows: both D471E and I527M (n = 9) or
both S464P and A534V (n = 2); both combinations were
associated with high-level resistance (MIC >32 mg/L). An
S464P change (n = 1) and an H481Y change (n = 1), associ-
ated with low-level resistance (MIC <6 mg/L) and high-level
resistance (MIC >32 mg/L), respectively, were also identiﬁed
(Fig. 1).
The rate of resistance to oxacillin was 61% when the
Etest was used on ISONP; it was 84% for the same drug on
MUHSP and 58% for cefoxitin on ISOAP. (Table 1).
FIG. 1. Multiple alignment of amino acid sequences of an RpoB fragment from Staphylococccus epidermidis isolates (n = 33) from patients with
prosthetic joint infections (numbering as for RpoB of Staphylococcus aureus (GenBank accession number CAA45512)).
TABLE 1. Antibiotic susceptibility (Etest) of Staphylococcus epidermidis (n = 33) isolated from prosthetic joint infections
Antibiotic Breakpoint MIC (mg/L)a MIC (mg/L) range MIC50 MIC90 Resistant (%)
Oxacillin (IsoSensitest)b 1/1c <0.016 to 24 0.38 2 61
Oxacillin (Mueller–Hinton)b,d 1/1c 0.125 to >256 128 >256 84
Cefoxitin 4/4 0.19 to >256 6 24 58
Gentamicin 1/1 0.032 to >256 32 64 79
Erythromycin 0.5/0.5 0.047 to >256 >256 >256 67
Clindamycin 0.5/2 0.023 to >256 >256 >256 67
Fusidic acid 0.5/0.5 0.016–16 0.047 12 39
Tigecycline 0.5/0.5 0.047–0.5 0.125 25 0
Rifampicin 1/1 <0.002 to >32 0.003 >32 39
Vancomycin 4/8 0.5–3 2 3 0
Linezolid 4/4 0.047–0.38 0.19 0.25 0
Daptomycin 1/1 0.094–1.5 0.25 0.75 3
Ciproﬂoxacin 1/1 0.047 to >32 >32 >32 79
Moxiﬂoxacin 0.5/1 0.016–6 2 3 64
Trimethoprim–sulphamethoxazole 16/32 0.64 to >640 >640 >640 82
Dalbavancin NA 0.003–0.047 0.032 0.047 NA
Ceftobiprole NA 0.094–1.5 0.5 1.5 NA
aSpecies-related breakpoints according to the Swedish Reference Group for Antibiotics (SRGA, http://www.srga.org). Breakpoints for S/I/R categorization, e.g. 4/8: S £ 4 mg/L
and R > 8 mg/L.
bThe Etest for oxacillin was performed using both ISONP and MUHSP. The Etest for all other antibiotics were performed using ISOAP.
cPharmacological breakpoint.
dOne isolate did not grow on MUHSP.
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However, the DDT with cefoxitin gave a 91% resistance
rate, and for moxalactam the 50th percentile were 22 mm
and the 90th percentile were 31 mm for the disc diffusion
test. No S ⁄ I ⁄R breakpoints deﬁned.
The mecA gene was detected in 85% of the isolates. Three
isolates, with a zone diameter of 23 mm (n = 2) or 26 mm
(n = 1) for cefoxitin, were negative for mecA but displayed
intermediate susceptibility according to the SRGA break-
points (R £ 21 mm and S ‡ 27 mm) and one isolate was
positive for mecA, but susceptible to cefoxitin. The two iso-
lates with a cefoxitin zone diameter of 23 mm had moxalac-
tam zone diameters of 28 and 31 mm.The isolate with a
cefoxitin zone diameter of 26 mm had a moxalactam zone
diameter of 23 mm. Overall, there was a good correlation
between size of the moxalactam zone diameter and the pres-
ence of mecA. However, the results concerning two isolates
were incongruent. One isolate with a zone diameter of
23 mm was mecA-negative and one isolate with a zone diam-
eter of 36 mm was mecA-positive. A comparison of the
results of the Etest for oxacillin, on ISONP, with the results
of mecA detection showed that 20 isolates (61%) were resis-
tant to oxacillin and mecA-positive. However, eight isolates
(24%) were susceptible to oxacillin but mecA-positive.
Accordingly, only ﬁve isolates (15%) were susceptible to oxa-
cillin and mecA-negative (Table 2). The same comparison, but
of the results obtained on MUHSP, showed that 27 isolates
(84%) were resistant to oxacillin and mecA-positive, whereas
only one isolate (3%) was susceptible to oxacillin but mecA-
positive and, accordingly, four isolates (13%) were suscepti-
ble to oxacillin and mecA-negative. One isolate did not grow
on MUHSP (Table 2). Regarding cefoxitin, 18 isolates (55%)
were resistant (Etest) and mecA-positive, ten isolates (30%)
were susceptible and mecA-positive, four isolates (12%) were
susceptible and mecA-negative, and one isolate (3%) was
resistant but mecA-negative (Table 2).
Regarding the ﬂuoroquinolones, 79% of the isolates were
resistant to ciproﬂoxacin and 64% were resistant to moxi-
ﬂoxacin, the latter with slightly lower MICs (Table 1).
According to the DDT with norﬂoxacin, 79% of the
isolates were resistant, and all of these were also resistant,
or intermediately susceptible, to ciproﬂoxacin and moxi-
ﬂoxacin.
Twenty-two isolates (67%) were resistant to clindamycin
(MIC >256 mg/L). All of these isolates were also resistant
to erythromycin (MIC >256 mg/L, except for one isolate
(MIC 32 mg/L)). No isolate was resistant to vancomycin,
whereas 79% were resistant to gentamicin, 82% to
trimethoprim–sulphamethoxazole and 39% to fusidic acid
(Table 1).
Regarding recently available antimicrobial agents, all iso-
lates (100%) were susceptible to tigecycline and linezolid,
and 97% were susceptible to daptomycin. In addition, two
novel antibiotics, dalbavancin and ceftobiprole, not yet com-
mercially available for routine use, were tested. The MIC50
and MIC90 of dalbavancin and ceftobiprole were 0.032 and
0.047 mg/L and 0.5 and 1.5 mg/L, respectively (Table 1). The
distributions of the MICs of dalbavancin and ceftobiprole are
shown in Fig. 2.
TABLE 2. MICs of oxacillin and cefoxitin, as related to the
presence of mecA (detected using real-time PCR), for
Staphylococcus epidermidis (n = 33) isolated from prosthetic
joint infections
mecA+ (n = 28) mecA) (n = 5)
Oxacillin-susceptible, ISONPa 8 5
Oxacillin-resistant, ISONPa 20 0
Oxacillin-susceptible, MUHSPa 1 4b
Oxacillin-resistant, MUHSPa 27 0
Cefoxitin-susceptiblea 10 4
Cefoxitin-resistanta 18 1
aThe Etest for oxacillin was performed using both ISONP and MUHSP. The
Etest for cefoxitin was performed using ISOAP.
bOne isolate did not grow on MUHSP.
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FIG. 2. Distribution of the MICs of dalbavancin (a) and ceftobiprole
(b), as determined with the Etest, for 33 Staphylococcus epidermidis
isolates from patients with prosthetic joint infections.
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Discussion
In the present study, the antimicrobial activities of 16 antibi-
otics against S. epidermidis isolated from PJIs were investi-
gated. Ninety-one per cent of the isolates were
multiresistant, whereas only two isolates were susceptible to
all the antibiotics tested, and one isolate was resistant to
cefoxitin only, as determined by DDT.
Among the isolates resistant to rifampicin (n = 13), one
or two SNPs associated with resistance were found in rpoB.
Rifampicin, in combination with an additional effective anti-
microbial agent, has been proposed as being ideal for the treat-
ment of PJI [3]. However, in the present study, 39% of the
isolates were resistant to rifampicin. Regarding the rpoB muta-
tions associated with rifampicin resistance, some of those
identiﬁed here have been described similarly for Staphylococcus
aureus but, as far as we know, not for S. epidermidis. The
A477V change has previously been described in S. aureus as
resulting in low-level resistance (MIC 1 mg/L) [26]. However,
the S. epidermidis isolate with the corresponding change in the
present study exhibited an MIC value of only 0.25 mg/L, and
was consequently regarded as susceptible.
Concerning the mutation variant 1 (Fig. 1), the non-synon-
ymous substitution (C ﬁ A) in amino acid codon 471
(D471E) has previously been described in S. aureus, but only
for in vitro-derived strains [27], whereas other non-synony-
mous nucleotide changes in the same codon have been
described in clinical isolates [26,28]. However, the I527M
change has resulted in high-level resistance (MIC >256 mg/L)
in S. aureus [28]. In mutation variant 2, the non-synonymous
substitution (T ﬁ C) in codon 464 (S464P) has previously
been described in S. aureus, resulting in a low level of resis-
tance (MIC 4 mg/L) [26]. However, the substitution
(C ﬁ T) in codon 534 (A534V) has not been described pre-
viously. The non-synonymous substitutions resulting in muta-
tion variants 3 and 4 (S464P and H481Y, respectively) have
been described previously in S. aureus, resulting in low-level
(MIC 4 mg/L) and high-level (MIC >256 mg/L) resistance,
respectively [26]. Accordingly, the results of the present
study clearly show that the development of rifampicin resis-
tance in S. epidermidis is similar to what has been reported in
S. aureus as well as in other bacterial species [26]. Thus, a sin-
gle SNP can lead to a dramatic increase in the MIC.
The majority (85%) of isolates carried mecA. However, a
higher proportion, depending on which agar was used for
oxacillin susceptibility testing, should have been regarded as
methicillin-susceptible according to the pharmacological MIC
breakpoints for oxacillin and the species-related MIC break-
points for cefoxitin, all recommended by the SRGA (http://
www.srga.org). When comparing ISONP and MUHSP, the
different results are a clear example of the effects of discrep-
ant test conditions for detecting resistance. There are other
studies showing that an addition of up to 5% NaCl improves
the detection of methicillin resistance [29,30]. In contrast,
the DDT for cefoxitin showed a higher correlation with the
presence of mecA than the Etest. However, the species-
related zone breakpoints for oxacillin using DDT have
recently been invalidated by the SRGA (http://www.srga.org).
Moxalactam susceptibility was investigated in order to
determine whether, with this compound, one could better
discriminate between mecA-positive and mecA-negative iso-
lates than with cefoxitin, especially in the case of isolates
showing intermediate susceptibility to cefoxitin (DDT zone
diameter 21–27 mm) [31]. The correlation between the
moxalactam zone diameters and the presence of mecA was
slightly better than that observed with cefoxitin, but it was
still not completely reliable. Consequently, detection of mecA
remains necessary prior to initiating treatment for infections
due to S. epidermidis strains that are intermediately suscepti-
ble to cefoxitin.
Fluoroquinolones have been recommended as the drugs
of ﬁrst choice for combination therapy with rifampicin for
the treatment of foreign-body infections such as PJIs [8].
Three ﬂuoroquinolones were tested in the present study,
but the proportion of susceptible isolates was rather similar
for all of them. However, slightly lower MICs of moxiﬂoxacin
were found, as compared with ciproﬂoxacin. The signiﬁcance
of this, however, is uncertain, as no clinical trial using moxi-
ﬂoxacin for the treatment of PJI has been published. Neverthe-
less, there are several clinical trials concerning PJIs in which
ciproﬂoxacin or levoﬂoxacin has been used in combination
with rifampicin, displaying impressive treatment outcomes
[8,18,32].
For additional commonly used antibiotics, e.g. clindamycin,
gentamicin and trimethoprim–sulphamethoxazole, a high level
of resistance was found. The high rate of gentamicin resis-
tance (79%) may be a result of the mandatory use of genta-
micin-containing cement in Sweden, and may also limit the
utilization of local application with gentamicin-containing col-
lagen sponges. There is only one published clinical study that
has examined the combination of rifampicin and clindamycin
[18], and this showed a lower cure rate than that obtained
with the combination of rifampicin and levoﬂoxacin. The
cumulative risk of treatment failure with the combination of
rifampicin and fusidic acid has been reported to be 12% [19].
Rifampicin is a strong inducer of the cytochrome P450
enzymes, including cytochrome 3A4 [33]. The exact meta-
bolic pathways for clindamycin and fusidic acid are not
known, but clindamycin is probably metabolized by hepatic
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cytochrome P450 enzymes and fusidic acid by cyto-
chrome 3A4 [34,35]. Theoretically, pharmacological interac-
tions could therefore occur, resulting in subtherapeutic
concentrations of clindamycin and fusidic acid, respectively,
during treatment with rifampicin and, eventually, in less
favourable treatment outcomes.
Almost all of the isolates were found to be highly suscep-
tible to the recently available antibiotics daptomycin (97%),
tigecycline (100%) and linezolid (100%). Several clinical trials,
although open and non-randomized, have shown promising
outcomes in the treatment of PJIs with linezolid, including
the combination with rifampicin [20,36]. However, the clini-
cal experience of treating PJIs with daptomycin and tigecy-
cline is limited [37]. In the present study, one daptomycin-
resistant isolate (MIC 1.0 mg/L) was found. The MIC of
vancomycin for this isolate was 2.0 mg/L. A relationship
between increased MICs of daptomycin and vancomycin has
been reported [38], as well as an increase in MIC during
long-term treatment with daptomycin [39].
The novel antimicrobial agents ceftobiprole and dalbavan-
cin have not yet been approved by the US Food and Drug
Administration or the European Medicines Agency (EMEA),
but preliminary in vitro and in vivo data have indicated the
potential usefulness of these antimicrobial agents for the
treatment of foreign-body infections [40,41]. The MICs of
these antimicrobial agents determined here indicate that they
may be considered for the treatment of PJIs, at least initially
until peroral antibiotics could be instituted.
In conclusion, S. epidermidis strains causing PJIs often show
multiresistance, including resistance to rifampicin, which is
mainly associated with one or two SNPs in rpoB. However,
some of the newer antimicrobial agents may provide poten-
tial alternatives for monotherapy or combination therapy
with rifampicin. Detection of mecA is necessary before initiat-
ing treatment of infection due to S. epidermidis when it dis-
plays intermediate susceptibility to cefoxitin.
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